Compare OTH & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTH | KRRO |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.2M | 105.0M |
| IPO Year | N/A | 2019 |
| Metric | OTH | KRRO |
|---|---|---|
| Price | $2.61 | $11.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $47.10 |
| AVG Volume (30 Days) | 22.0K | ★ 150.3K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.35 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,271,000.00 |
| Revenue This Year | N/A | $145.97 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $600.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.95 | $5.20 |
| 52 Week High | $3.75 | $55.89 |
| Indicator | OTH | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 50.28 |
| Support Level | $2.03 | $10.55 |
| Resistance Level | $2.72 | $12.54 |
| Average True Range (ATR) | 0.22 | 0.85 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 88.24 | 41.26 |
Off The Hook YS Inc operates as a nationwide leader in the yacht and boat dealership industry, offering a comprehensive suite of services that spans the entire boat value chain. The company operates as two segments: Boat Sales and Azure Funding. Boat Sales includes Specializing in the buying, selling, and wholesaling of yachts and boats, having a boat dealership created to run Yellow Fin sales in Miami; and Azure Funding includes a recreational loan broker and lender providing financing solutions for individuals, dealerships, and brokerages.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.